CheckMan Stock Market Overview
Trending Stocks
Red List
In Today's Headlines
NEW YORK, Aug. 21, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Photronics, Inc. (NASDAQ: PLAB) between December 10, 2025 and May 27, 2026, inclusive (the “Class Period”), of the important September 4, 2026 lead plaintiff deadline.
Prospect Capital reported Q4'26 NII of $0.15 per share, beating estimates, but faced portfolio contraction and declining net investment income vs. last year. PSEC's dividend cut to $0.035 per share improved dividend coverage to over 130% in Q4, with stable asset quality evidenced by a 0.7% non-accrual percentage. The portfolio shift toward 72.5% first lien loans enhances quality, potentially easing concerns over recent NAV declines and dividend cuts.
SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.
WDAY's AI Research team is advancing enterprise AI with gains in memory, speed and accuracy while tackling privacy, explainability and governance.
CBRS CS-4 boosts inference speed and power efficiency as cloud demand surges, while NVIDIA and AMD intensify competition.
WPP alleges in a legal filing that a former exec improperly leaked sensitive information in his lawsuit against the company. WPP is asking the court to seal several paragraphs, figures, and exhibits from the lawsuit.
NEW YORK, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Cogent Communications Holdings, Inc. (“Cogent” or the “Company”) (NASDAQ: CCOI) on behalf of investors that purchased or otherwise acquired Cogent securities between February 29, 2024 and May 1, 2026 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in Cogent and have suffered losses, you may CLICK HERE to contact us.
A rare split is opening up inside the Bitcoin (CRYPTO:BTC) miner cohort on Friday, and it isn't about the coin.
ONDS pairs surging revenues, a $613M backlog and a lower valuation with integration risks, while RCAT faces a steep second-half ramp.
DCI rides strong Mobile Solutions and Life Sciences growth, expands through acquisitions and raises shareholder returns despite pressure in Industrial Solutions.